#1 Clinical Trials Search in Europe

Montelukast

Montelukast, a leukotriene receptor antagonist, has been the subject of numerous clinical trials investigating its efficacy in treating various medical conditions. This article explores the use of Montelukast in clinical studies, focusing on its potential benefits for asthma, allergic rhinitis, COVID-19, and other respiratory conditions. We’ll examine the drug’s mechanism of action, dosage, and potential side effects, as well as its performance in different patient populations.

Table of Contents

What is Montelukast?

Montelukast is a medication primarily used to treat asthma and allergic rhinitis (hay fever). It belongs to a class of drugs called leukotriene receptor antagonists. Montelukast is also known by its brand name Singulair[1]. Other brand names include Aireez and Asmakast[2].

What Conditions Does Montelukast Treat?

Montelukast is used to treat several respiratory conditions, including:

  • Asthma: A chronic lung condition that causes difficulty breathing[1]
  • Allergic Rhinitis: Also known as hay fever, this condition causes sneezing, runny nose, and itchy eyes[1]
  • Bronchopulmonary Dysplasia (BPD): A chronic lung disease that affects premature infants[3]
  • Wheezing in young children: Recurrent episodes of noisy breathing in children under 2 years old[4]

How Does Montelukast Work?

Montelukast works by blocking the action of substances in the body called leukotrienes. Leukotrienes are chemicals that cause inflammation in the airways, leading to symptoms of asthma and allergies. By blocking these substances, Montelukast helps to:

  • Reduce inflammation in the airways
  • Prevent bronchoconstriction (narrowing of the airways)
  • Decrease the number of eosinophils (a type of white blood cell) in the airways and blood

This action results in improved control over asthma and allergic rhinitis symptoms[1].

Dosage and Administration

Montelukast is available in different forms and dosages depending on the patient’s age and condition:

  • Adults and adolescents (15 years and older): 10 mg tablet once daily[1]
  • Children aged 6-14 years: 5 mg chewable tablet once daily[1]
  • Children aged 2-5 years: 4 mg chewable tablet once daily[1]
  • Infants and toddlers (6 months to 2 years): Dosage based on weight, typically 4 mg once daily[4]

Montelukast is usually taken once daily in the evening[1]. It’s important to follow your doctor’s instructions regarding dosage and timing.

Clinical Studies and Effectiveness

Several clinical studies have been conducted to evaluate the effectiveness of Montelukast:

  • A study on children under 2 years with recurrent wheezing showed improvements in lung function after 4 weeks of treatment with Montelukast[4].
  • Research on premature infants suggests that Montelukast may help prevent bronchopulmonary dysplasia, a chronic lung condition in preterm babies[3].
  • Studies in adults and children with asthma and allergic rhinitis have shown that Montelukast can improve symptoms and quality of life[1].

Side Effects and Safety

While Montelukast is generally well-tolerated, some side effects may occur. Common side effects reported in clinical trials include:

  • Headache
  • Ear infection (otitis media)
  • Upper respiratory infection
  • Sore throat (pharyngitis)[1]

It’s important to note that the safety profile of Montelukast is well-established, with a 20-year safety record[5]. However, as with any medication, patients should report any unusual symptoms to their healthcare provider.

Use in Special Populations

Montelukast has been studied in various populations:

  • Pregnant women: Some studies have included pregnant women, suggesting that Montelukast may be a safe option for managing asthma during pregnancy[5].
  • Older adults: Montelukast has been studied in older adults and may be a suitable option for managing asthma in this population[5].
  • Infants and young children: Studies have been conducted on the use of Montelukast in children as young as 6 months old[4].

Drug Interactions

While Montelukast is generally safe, it’s important to be aware of potential drug interactions. One study investigated the interaction between Montelukast and pineapple juice, highlighting the importance of discussing all medications and dietary habits with your healthcare provider[6].

Aspect Details
Primary Conditions Studied Asthma, Allergic Rhinitis, COVID-19, Bronchopulmonary Dysplasia, Wheezing in children
Mechanism of Action Selective blocker of CysLT1 receptor, inhibiting physiologic actions of LTD4
Common Dosages Adults: 10mg daily, Children: 4-5mg daily (age-dependent), Preterm infants: weight-based dosing
Primary Outcome Measures Symptom severity, lung function, biomarkers of inflammation (CRP, IL-6), quality of life
Secondary Outcome Measures Duration of symptoms, hypoxemia incidence, healthcare service use, adverse events
Potential Benefits Reduced inflammation, improved respiratory function, potential attenuation of COVID-19 symptoms
Safety Considerations Generally well-tolerated, common side effects include headache and upper respiratory infection
Special Populations Studies include adults, children, and preterm infants
Ongoing Research Areas COVID-19 treatment, prevention of bronchopulmonary dysplasia in preterm infants

FAQ

  • What is Montelukast and how does it work? Montelukast is an orally active compound that binds with high affinity and selectivity to the CysLT1 receptor. It inhibits the physiological actions of LTD4 at the CysLT1 receptor, resulting in reduced bronchoconstriction and decreased airway and blood eosinophils. This leads to improved control over asthma and allergic rhinitis symptoms.
  • In which medical conditions is Montelukast being studied? Montelukast is being studied in various conditions, including asthma, allergic rhinitis, COVID-19, bronchopulmonary dysplasia in preterm infants, and wheezing in young children. Clinical trials are exploring its efficacy in these different areas to determine its potential benefits.
  • What are the common dosages of Montelukast used in clinical trials? The dosage of Montelukast varies depending on the study and patient population. In adults, a common dosage is 10mg once daily. For children, dosages may range from 4mg to 5mg, depending on age. In some studies, such as those involving preterm infants, dosages are adjusted based on weight.
  • Are there any potential side effects of Montelukast? While Montelukast is generally well-tolerated, some reported side effects include headache, upper respiratory infection, and pharyngitis. It's important to note that the safety profile may vary depending on the patient population and specific condition being treated.
  • How is the effectiveness of Montelukast measured in clinical trials? The effectiveness of Montelukast is measured through various outcomes, depending on the condition being studied. These may include changes in symptom severity, lung function tests, biomarkers of inflammation (such as C-reactive protein and interleukin IL-6), quality of life assessments, and in some cases, the incidence of complications or mortality rates.

Ongoing Clinical Trials on Montelukast

  • A study comparing montelukast to placebo for reducing pain in patients with erosive osteoarthritis of the hands

    Recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Italy Portugal Spain

  • Study on Montelukast for COVID-19 Patients at Higher Risk of Complications in the Community

    Not yet recruiting

    3 1 1 1
    Investigated drugs:
    The Netherlands

  • Comparison of montelukast 10 mg capsules and montelukast 10 mg film-coated tablets in healthy volunteers to evaluate how the medicine is absorbed.

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study for Adults with Very High-Risk T-Cell Acute Lymphoblastic Leukemia Using Daratumumab and a Drug Combination

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Italy

  • Study on Montelukast for Patients with Peripheral Artery Disease Undergoing Endovascular Treatment

    Not recruiting

    3 1 1
    Investigated drugs:
    Poland

  • Study on Montelukast for Pain Relief in Patients with Erosive Hand Osteoarthritis

    Not recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on the Effects and Safety of Dupilumab for Children Aged 2 to Under 6 with Uncontrolled Asthma or Severe Asthmatic Wheeze

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia France Germany Greece Hungary Italy +3

  • Study of LTX-315 and Pembrolizumab for Patients with Advanced Melanoma Resistant to PD-1/PD-L1 Therapy

    Not recruiting

    2 1 1 1
    Investigated drugs:
    France Norway Spain

  • Study on Montelukast for COVID-19 Patients at Higher Risk in Primary Care

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

Glossary

  • Montelukast: An orally active compound that acts as a leukotriene receptor antagonist, used to treat asthma and allergic rhinitis by reducing inflammation and bronchoconstriction in the airways.
  • CysLT1 receptor: A type of receptor in the body that responds to leukotrienes, which are inflammatory molecules. Montelukast works by blocking these receptors.
  • Bronchopulmonary Dysplasia (BPD): A chronic lung disease that affects premature infants, characterized by inflammation and scarring in the lungs.
  • FluPro PLUS score: A measure used to assess symptom severity in respiratory conditions, including COVID-19.
  • C-Reactive Protein (CRP): A protein produced by the liver in response to inflammation, used as a biomarker to measure inflammation levels in the body.
  • Interleukin IL-6: A protein involved in immune responses and inflammation, often used as a biomarker in clinical studies.
  • Hypoxemia: A condition where there is a low level of oxygen in the blood, often measured using pulse oximetry.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Bioequivalence: A comparison of the biological equivalence of two preparations of a drug, usually between an original brand-name drug and a generic version.
  • Cytokine storm: An severe immune reaction where the body releases too many cytokines into the blood too quickly, potentially leading to organ damage.

References

  1. https://clinicaltrials.gov/study/NCT03380975
  2. https://clinicaltrials.gov/study/NCT02480049
  3. https://clinicaltrials.gov/study/NCT01717625
  4. https://clinicaltrials.gov/study/NCT00775697
  5. https://clinicaltrials.gov/study/NCT04389411
  6. https://clinicaltrials.gov/study/NCT04374981